Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts by Tsou, Pei-Suen et al.
Tsou et al. Arthritis Research & Therapy 2014, 16:411
http://arthritis-research.com/content/16/4/411RESEARCH Open AccessLipoic acid plays a role in scleroderma: insights
obtained from scleroderma dermal fibroblasts
Pei-Suen Tsou1,2*, Beatrix Balogh2, Adam J Pinney2, George Zakhem2, Ann Lozier2, M Asif Amin3,
William A Stinson2, Elena Schiopu1,3, Dinesh Khanna1,3, David A Fox3 and Alisa E Koch4,3Abstract
Introduction: Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis of the skin and organs.
Increase in oxidative stress and platelet-derived growth factor receptor (PDGFR) activation promote type I collagen
(Col I) production, leading to fibrosis in SSc. Lipoic acid (LA) and its active metabolite dihydrolipoic acid (DHLA) are
naturally occurring thiols that act as cofactors and antioxidants and are produced by lipoic acid synthetase (LIAS).
Our goals in this study were to examine whether LA and LIAS were deficient in SSc patients and to determine the
effect of DHLA on the phenotype of SSc dermal fibroblasts. N-acetylcysteine (NAC), a commonly used thiol
antioxidant, was included as a comparison.
Methods: Dermal fibroblasts were isolated from healthy subjects and patients with diffuse cutaneous SSc. Matrix
metalloproteinase (MMPs), tissue inhibitors of MMPs (TIMP), plasminogen activator inhibitor 1 (PAI-1) and LIAS were
measured by enzyme-linked immunosorbent assay. The expression of Col I was measured by immunofluorescence,
hydroxyproline assay and quantitative PCR. PDGFR phosphorylation and α-smooth muscle actin (αSMA) were
measured by Western blotting. Student’s t-tests were performed for statistical analysis, and P-values less than 0.05
with two-tailed analysis were considered statistically significant.
Results: The expression of LA and LIAS in SSc dermal fibroblasts was lower than normal fibroblasts; however, LIAS
was significantly higher in SSc plasma and appeared to be released from monocytes. DHLA lowered cellular
oxidative stress and decreased PDGFR phosphorylation, Col I, PAI-1 and αSMA expression in SSc dermal fibroblasts.
It also restored the activities of phosphatases that inactivated the PDGFR. SSc fibroblasts produced lower levels of
MMP-1 and MMP-3, and DHLA increased them. In contrast, TIMP-1 levels were higher in SSc, but DHLA had a
minimal effect. Both DHLA and NAC increased MMP-1 activity when SSc cells were stimulated with PDGF. In
general, DHLA showed better efficacy than NAC in most cases.
Conclusions: DHLA acts not only as an antioxidant but also as an antifibrotic because it has the ability to reverse
the profibrotic phenotype of SSc dermal fibroblasts. Our study suggests that thiol antioxidants, including NAC, LA,
or DHLA, could be beneficial for patients with SSc.Introduction
The pathogenesis of scleroderma (that is, systemic scle-
rosis (SSc)) includes impaired immunity, vascular abnor-
malities and tissue fibrosis. Despite the effort expended
to understand the disease, the mechanism underlying
clinical manifestations of SSc remains elusive. We and* Correspondence: ptsou@umich.edu
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stated.others have reported that oxidative stress plays an im-
portant role in SSc pathogenesis [1,2], and researchers in
a considerable number of clinical studies have also re-
ported that oxidative stress is involved in SSc [3–6].
Interestingly, SSc sera have the ability to induce reactive
oxygen species (ROS) production in endothelial cells
and fibroblasts [5]. Allanore et al. reported that plasma
markers of oxidative stress, such as protein carbonyls,
nitrosothiols and malondialdehyde, were significantly
higher in patients with SSc than in healthy subjects [3].
In addition, the serum levels of 8-isoprostane, another
marker for oxidative stress, were found to be elevated ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 SSc patient and healthy volunteer characteristicsa
SSc Diffuse
SSc
Limited
SSc
Healthy
subjects
(n = 60) (n = 36) (n = 24) (n = 38)
Age (yr) 57.0 ± 1.4 55.7 ± 1.8 58.2 ± 2.2 44.3 ± 2.4
Sex F46/M14 F27/M9 F21/M3 F26/M12
Disease duration (yr) 8.7 ± 1.2 5.4 ± 1.0 13.8 ± 2.2 NA
mRSS 13.4 ± 1.5 18.5 ± 2.0 5.3 ± 0.8 NA
Raynaud’s phenomenon 60 36 24 NA
Early diseaseb 31 24 7 NA
Deceased 1 0 1 NA
Digital ulcers 18 14 4 NA
Teleangectasias 38 21 17 NA
Gastrointestinal disease 53 31 20 NA
ILD 30 21 8 NA
PAH 18 8 9 NA
Renal involvement 5 3 2 NA
aILD, Interstitial lung disease; mRSS =Modified Rodnan skin score (0 to 51);
PAH, Pulmonary arterial hypertension; SSc, Scleroderma. bEarly disease: Less
than 5 years. Data are mean ± SEM or raw numbers.
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nary fibrosis, renal vascular damage and immunological
abnormalities [4].
In addition to the increased markers for oxidative
stress, studies of decreased antioxidant defense capacity
in SSc patients have been reported [6,7]. Several clinical
trials were therefore initiated to assess the efficacy of an-
tioxidants in SSc [3,8–10]. Calcium channel blockers
(dihydropyridines such as nifedipine) significantly low-
ered ROS and increased plasma thiol levels [3]. The anti-
oxidative property of nifedipine derives from its ability
to reduce superoxide (O2•
−) production from peripheral
blood monocytes through the inhibition of protein
kinase C (PKC)–dependent protein phosphorylation and
PKC activity [10]. Use of a lipid-lowering agent/antioxi-
dant, probucol, not only reduced low-density lipoprotein
oxidation susceptibility but also led to significant im-
provement in Raynaud’s episodes [8]. However, one trial
of an antioxidant mixture together with allopurinol
failed to show any clinical benefit or improvement in the
ROS profile in SSc patients [9]. The purpose of incor-
porating of allopurinol in that study was to reduce free
radical production by inhibiting xanthine oxidase. Allo-
purinol also produces O2•
− [11], however, which might
be one of the reasons for the negative study result.
The presence of thiols is an indication of oxidative
stress in biological systems, as they are very sensitive to
ROS and easily oxidized, and therefore they play a cru-
cial role in maintaining the redox state in cells. We
showed previously that the free thiol content in SSc der-
mal fibroblasts was significantly lower than that in nor-
mal (NL) cells [1]. It has also been shown that total
plasma thiols in SSc patients were significantly lower
than in healthy subjects [3,12]. Glutathione (GSH), the
most abundant thiol compound in the body, was signifi-
cantly lower in erythrocytes and dermal fibroblasts from
SSc patients compared to the control population [6,13].
In this study, we focused on another crucial thiol, lipoic
acid (LA), and its metabolite dihydrolipoic acid (DHLA),
in SSc. LA is produced in small amounts by the body via
lipoic acid synthetase (LIAS) and acts as the coenzyme for
pyruvate dehydrogenase and α-ketoglutarate dehydrogen-
ase in the mitochondria. Together with its reduced form
DHLA, it forms a redox couple, and the two act synergis-
tically as biological antioxidants when given orally. In
addition, they are capable of regenerating GSH, vitamin C
and vitamin E from their oxidized forms [14,15]. In con-
trast to N-acetylcysteine (NAC), a commonly used thiol
antioxidant in numerous studies [1,16–18], the LA-DHLA
pair appears to provide more benefits as it has a better an-
tioxidative profile and less toxicity. In this study, we were
interested in exploring whether LA and LIAS levels are
different among healthy subjects and SSc patients, and,
because DHLA has more antioxidant activity than LA, weexamined whether DHLA affects the profibrotic pheno-
type of dermal fibroblasts isolated from patients with dif-
fuse SSc.
Methods
Patients
All SSc patients fulfilled the American College of Rheu-
matology criteria for classification of SSc [19]. Plasma
samples were collected from SSc patients and healthy
subjects. Subject characteristics are listed in Table 1.
Two punch biopsies (4 mm) were taken from the fore-
arms of SSc patients with diffuse cutaneous variants.
Normal skin tissue was obtained from healthy volunteers
as well as the tissue procurement service provided by
the University of Michigan Hospital. Written informed
consent was obtained for all subjects, and the study was
approved by the University of Michigan Institutional
Review Board.
Cell culture
Both NL and SSc dermal fibroblasts were isolated from
human skin. The tissue was digested using enzyme diges-
tion solution containing 2.4 U/ml dispase, 650 U/ml type
II collagenase and 10,000 Dornase U/ml DNase. Dermal
fibroblasts were maintained in RPMI 1640 medium with
10% fetal bovine serum (FBS), penicillin and streptomycin.
Passages between 4 and 8 were used. Before experiments,
NL and SSc dermal fibroblasts were switched to RPMI
1640 medium with 0.1% FBS. When needed, 500 μM
DHLA (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
was added to the cell culture media. The incubation time
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were harvested for oxidative stress detection (48 hours)
or α-smooth muscle actin (αSMA)/collagen analysis
(72 hours). Monocytes from healthy subjects and SSc pa-
tients were isolated using Percoll gradient as previously
described [20]. They were plated in six-well plates, and
the nonadherent cells were washed off after 2 hours of
seeding. The adherent cells were monocytes and cultured
in RPMI media in the presence of FBS. Before stimulation,
they were switched to RPMI media without FBS. The con-
ditioned media were collected for LIAS analysis.
Oxidative stress detection
Cellular O2•
− was measured using dihydroethidium
(Invitrogen, Carlsbad, CA, USA). The nuclei were stained
using 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen).
Fluorescence was detected using an Olympus FV-500
confocal microscope, and photographs were taken at
400× magnification. Cellular peroxynitrite levels were
detected using 2′,7′-dichlorodihydrofluorescein diacetate
[13]. Both NL and SSc dermal fibroblasts were plated in
96-well plates (5 × 104 cells/well, 200 μl/well) and incu-
bated in RPMI 1640 medium (0.1% FBS), with or without
20 mM NAC or 500 μM DHLA, for 48 hours at 37°C.
After the incubation, cells were then treated with 200 μM
2′,7′-dichlorohihydrofluorescein diacetate in phosphate-
buffered saline for 1 hour at 37°C. The fluorescence inten-
sity was measured using a fluorescence plate reader, and
the excitation and emission wavelengths used were 490
and 533 nm.
mRNA extraction and quantitative RT-PCR
Total RNA was isolated from dermal fibroblasts using
RNeasy Mini RNA isolation kits (QIAGEN, Valencia, CA,
USA). cDNA was prepared using Verso cDNA synthesis
kits (Thermo Scientific, Asheville, NC, USA). Quantitative
PCR was performed using SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) with specific
primers for type I collagen (Col I), density-enhanced phos-
phatase 1 (DEP-1), Src homology 2 domain–containing
protein tyrosine phosphatase 2 (SHP-2) and β-actin. All
samples were run in duplicate using Applied Biosystems
Real-Time PCR System and analyzed using 7500 Applied
Biosystems software.
Detection of platelet-derived growth factor receptor
phosphorylation
Both NL and SSc dermal fibroblasts were incubated with
or without 500 μM DHLA overnight and stimulated with
platelet-derived growth factor (PDGF). Cell lysates were
obtained, and equal amounts of lysate proteins were incu-
bated with immobilized mouse anti-human phospho-
tyrosine monoclonal antibody (Cell Signaling Technology,
Danvers, MA, USA) overnight at 4°C. Rabbit anti-humanplatelet-derived growth factor receptor β (PDGFRβ) anti-
body (Cell Signaling Technology) was used to probe for
phosphorylated PDGFR after SDS-PAGE and Western
blotting. The immunoprecipitated, tyrosine-phosphory-
lated proteins were detected using mouse anti-human
phospho-tyrosine antibody (Cell Signaling Technology).
Immunofluorescence
Cells grown in eight-well chambers were fixed and
blocked with FBS before being probed with mouse anti-
human Col I monoclonal antibody (Abcam, Cambridge,
MA, USA), rabbit anti-human αSMA antibody (Abcam)
or rabbit anti-LA antibody (Calbiochem, San Diego, CA,
USA). Slides were subsequently incubated with Alexa
Fluor 488 donkey anti-mouse antibody or Alexa Fluor 488
donkey anti-rabbit antibody (Molecular Probes/Invitrogen,
Eugene, OR, USA). The nuclei were stained with DAPI.
Western blotting
Equal amounts of cell lysate were loaded onto polyacry-
lamide gels and separated by SDS-PAGE. The proteins
were then transferred onto nitrocellulose membranes via
Western blotting. The blots were probed with antibodies
to LIAS (Thermo Scientific), αSMA (Abcam) or β-actin
(Sigma-Aldrich, St Louis, MO, USA).
Phosphatase activity assay
Phosphatase activity assays were carried out using the
DuoSet Intracellular kits from R&D Systems (Minneapolis,
MN, USA). Antibodies that capture both active and in-
active protein tyrosine phosphatase 1B (PTP1B), SHP-2 or
DEP-1 were immobilized. After unbound proteins were
washed away, a synthetic phosphopeptide substrate that
was dephosphorylated by active phosphatases was added
to generate free phosphate and unphosphorylated pep-
tide. The free phosphate was detected by a sensitive dye-
binding assay using malachite green and molybdic acid.
The activity of the phosphatase was determined by calcu-
lating the rate of phosphate release.
Enzyme-linked immunosorbent assay
Total matrix metalloproteinase 1 (MMP-1), MMP-3, tis-
sue inhibitor of matrix metalloproteinase 1 (TIMP-1) or
plasminogen activator inhibitor 1 (PAI-1) in cell culture
medium was measured using enzyme-linked immuno-
sorbent assay (ELISA) kits from R&D Systems. Briefly,
goat anti-human primary antibodies were coated on a
96-well plate before samples and standards were added.
The sandwich ELISA was completed by adding biotinyla-
ted goat anti-human antibodies, followed by streptavidin-
horseradish peroxidase and substrate solution. The optical
density of each well was measured using an ELISA plate
reader. Plasma LIAS levels were measured using an LIAS
ELISA kit from Cusabio Biotech Co (Wuhan, China).
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Lyte Plus 520 MMP-9 assay kit (AnaSpec, Fremont, CA,
USA). Endogenously active MMP-1 activity in culture
media was detected using a SensoLyte Plus MMP-1 assay
kit from AnaSpec.Hydroxyproline measurement
Hydroxyproline content in cell culture media was mea-
sured using a hydroxyproline assay kit (Sigma-Aldrich).
Culture media were treated with concentrated hydro-
chloric acid and hydrolyzed at 120°C for 3 hours. Hy-
droxyproline standards, along with 50 μl of the samples,
were transferred to a 96-well plate and placed in a 60°C
oven until the wells were dried. Chloramine T/oxidation
buffer and subsequently the diluted 4-(dimethylamino)
benzaldehyde was then added to the wells and incubated
for 90 minutes at 60°C. The absorbance was measured at
560 nm using a plate reader.Statistical analysis
The results were expressed as mean ± SEM. To deter-
mine the differences between the groups, Student’s
t-tests were performed. P-values less than 0.05 with two-
tailed analysis were considered statistically significant.Results
LA and LIAS expression
Because LA is synthesized in the body, we first examined
whether LA expression differed in SSc patients com-
pared to healthy subjects. We found that the cellular
expression of LA in SSc dermal fibroblasts was lower
compared to NL cells (Figure 1A). In addition, the
enzyme that produces LA, LIAS, was significantly lower
in SSc dermal fibroblasts (Figure 1B). In contrast, the
plasma LIAS levels were significantly elevated in SSc
patients, specifically those with diffuse SSc or intersti-
tial lung disease (ILD), compared to healthy subjects
(Figure 1C). Patients with limited SSc or pulmonary
hypertension showed no difference in LIAS levels. To
determine the source of the released LIAS levels de-
tected in plasma, we measured LIAS in conditioned
media collected from dermal fibroblasts, dermal endo-
thelial cells and monocytes from both healthy subjects
and SSc patients. Only the culture media from mono-
cytes released detectable LIAS levels. Although no sta-
tistical significance was reached between NL and SSc
groups, there was a significant difference between NL
and diffuse SSc (P < 0.05) (Figure 1D). Similar to what
was seen in the plasma (Figure 1C), monocytes from
limited SSc patients did not produce elevated amounts
of LIAS (P < 0.05 between diffuse and limited SSc)
(Figure 1D).Oxidative stress
Because LA and its metabolite DHLA can act as anti-
oxidants, we examined their antioxidative capacity in
dermal fibroblasts. We found that O2•
− was significantly
higher in SSc dermal fibroblasts (Figure 1E) and that
DHLA had no effect. To examine whether DHLA affects
other oxidative products, we measured peroxynitrite and
found that it was elevated in SSc dermal fibroblasts.
NAC and DHLA lowered it significantly (Figure 1F).
This suggests that there is increased oxidative stress in
SSc dermal fibroblasts and that different thiols affect dif-
ferent forms of oxidative products.
Phosphorylation of platelet-derived growth factor
receptor
Because LA was lower in SSc dermal fibroblasts and re-
lieved oxidative stress, we hypothesized that adding
DHLA, its active metabolite, to the cells would change
their profibrotic phenotype back to normal. We first ex-
amined the effect of DHLA on PDGFR activation. In NL
dermal fibroblasts, PDGF-stimulated PDGFR phospho-
rylation (p-PDGFR) was maximal at 30 minutes and de-
creased significantly at 1 hour (Figure 2A). In contrast,
p-PDGFR maximized at 10 minutes and remained phos-
phorylated at 1 hour in SSc dermal fibroblasts. In the
presence of DHLA, p-PDGFR peaked at 10 and 30 mi-
nutes for NL fibroblasts. However, PDGF did not induce
p-PDGFR in the presence of DHLA in SSc fibroblasts.
The time course of p-PDGFR with or without DHLA
significantly decreased the extent of p-PDGFR in both
NL and SSc. This suggests that the excessive p-PDGFR
seen in SSc dermal fibroblasts is due to increased oxida-
tive stress, as a thiol antioxidant could reduce it.
Phosphatase activities and expression
Because DHLA affects p-PDGFR, we hypothesized that
DHLA restores the activities of thiol-sensitive phospha-
tases by decreasing the oxidative stress in SSc dermal
fibroblasts, thereby decreasing p-PDGFR. Because PTP1B,
DEP-1 and SHP-2 have been shown to dephosphorylate
the PDGFR, we examined their expression and activities
with or without DHLA in NL and SSc fibroblasts. SHP-2
mRNA was significantly lower in SSc (Additional file 1:
Figure S1), and the presence of the antioxidants increased
it, with NAC reaching statistical significance. On the other
hand, DEP-1 mRNA was significantly higher in SSc
dermal fibroblasts compared to NLs, whereas the thiol
antioxidants did not affect the mRNA levels. Interest-
ingly, DEP-1 protein expression was elevated in SSc fi-
broblasts under basal conditions, and addition of NAC
further increased it in both NL and SSc cells (data not
shown).
We found that PTP1B was significantly inactivated in
SSc dermal fibroblasts (Figure 2B). The addition of thiols
Figure 1 The levels of lipoic acid, lipoic acid synthetase and oxidative stress in normal and scleroderma fibroblasts and plasma.
(A) Immunostaining of lipoic acid (LA) in normal (NL) and scleroderma (SSc) dermal fibroblasts (n = 3 subjects). IgG, Immunoglobulin G. (B) The
expression of lipoic acid synthetase (LIAS) in dermal fibroblasts was examined by Western blotting (n = 6 healthy and 5 SSc subjects). (C) Plasma
LIAS levels in healthy subjects and SSc patients. ILD, Interstitial lung disease; PAH, Pulmonary arterial hypertension. (D) LIAS levels in culture media
from monocytes isolated from healthy subjects and SSc patients. (E) Cellular superoxide levels were detected with dihydroethidium. These
representative images are from five healthy and five SSc subjects. (F) The effect of dihydrolipoic acid (DHLA) and N-acetylcysteine (NAC) on
peroxynitrite levels was measured (n = 4 subjects, P < 0.05). Results are expressed as mean ± SEM. P < 0.05 was considered significant.
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activity was significantly lower in SSc dermal fibroblasts
(Figure 2C). Whereas addition of NAC had no effect on
SHP-2 activity in SSc fibroblasts, DHLA significantly re-
stored it. On the other hand, DEP-1 activity was similar
in NL and SSc fibroblasts; however, addition of antioxi-
dants increased DEP-1 activity in SSc dermal fibroblasts
(Figure 2D). DHLA was more effective than NAC, as it
caused a significant increase in DEP-1 activity in SSc
cells compared to that at the basal level. Taken together,
these results imply that the increased oxidative stress in
SSc inactivates phosphatases responsible for PDGFR
dephosphorylation, resulting in increased p-PDGFR. The
presence of antioxidants not only eliminates oxidativesubstances but also restores phosphatase activities,
thereby decreasing the extent of p-PDGFR.
Type I collagen expression
Because PDGFR activation can lead to excess Col I pro-
duction, we hypothesized that DHLA can decrease Col I
in these cells. As expected, there was more Col I staining
in SSc dermal fibroblasts than in NL cells (Figure 3A).
In the presence of DHLA, Col I in SSc dermal fibro-
blasts decreased to levels similar to those observed in
NL cells. To further quantify the levels of Col I, we mea-
sured hydroxyproline in the cell culture media in the
presence or absence of DHLA (Figure 3B). Similar
to what is shown in Figure 3A, hydroxyproline was
Figure 2 The effect of dihydrolipoic acid on the platelet-derived growth factor receptor pathway and phosphatases. (A) Phosphorylated
platelet-derived growth factor receptor (p-PDGFR) after PDGF stimulation at various time points (n = 3 NL and SSc subjects). NS, Nonstimulated.
Enzymatic activities of protein tyrosine phosphatase 1B (PTP1B) (B), Src homology 2 domain–containing protein tyrosine phosphatase 2 (SHP-2)
(C) and density-enhanced phosphatase 1 (DEP-1) (D) in fibroblasts with or without dihydrolipoic acid (DHLA) or N-acetylcysteine (NAC). Results
are expressed as mean ± SEM. P < 0.05 was considered significant.
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of DHLA decreased it. Stimulating the cells with PDGF
increased hydroxyproline levels significantly in both NL
and SSc fibroblasts, whereas DHLA diminished this
effect (Figure 3B). We also determined the effect of
DHLA at the mRNA level. At basal level and at 10 and
45 minutes after PDGF stimulation, Col I mRNA was
significantly higher in SSc fibroblasts (Figure 3C). After
4 hours of PDGF stimulation, Col I mRNA significantly
decreased compared to NS. DHLA significantly de-
creased Col I mRNA levels in SSc fibroblasts at basal
levels and 10 minutes after PDGF incubation. These re-
sults indicate that, in SSc, enhanced PDGFR activation
leads to more Col I synthesis. By acting on scavenging
ROS and deactivating the PDGFR, DHLA decreased Col
I production.
To further investigate the effect of DHLA on trans-
forming growth factor β (TGF-β), NL and SSc dermalfibroblasts were incubated with 10 ng/ml TGF-β for
48 hours and Col I production was examined by mea-
suring both qPCR and hydroxyproline content. In NL fi-
broblasts, the addition of TGF-β significantly increased
the hydroxyproline content (Figure 3D). In contrast, the
presence of DHLA significantly decreased it. Hydroxy-
proline levels were significantly elevated in conditioned
media from SSc dermal fibroblasts compared to NL
cells, and they increased significantly after TGF-β incu-
bation. Although the addition of DHLA significantly re-
duced hydroxyproline levels in SSc cells, the amount of
hydroxyproline was still significantly higher compared to
that in NL fibroblasts.
The mRNA levels of Col I were also examined after
cells were treated with TGF-β (Figure 3E). Col I mRNA
levels were significantly elevated in SSc dermal fibro-
blasts compared to NL cells. TGF-β induced Col I
mRNA in both NL and SSc dermal fibroblasts, and the
Figure 3 The expression of type I collagen in fibroblasts. (A) Immunostaining of type I collagen (Col I) in normal (NL) and scleroderma (SSc)
dermal fibroblasts (n = 3 NL and 4 SSc subjects). IgG, Immunoglobulin G. (B) Hydroxyproline content was measured in cell culture media. As illustrated
by the images shown in (A), hydroxyproline levels were elevated in SSc dermal fibroblasts compared to NL cells. Platelet-derived growth factor (PDGF)
significantly increased hydroxyproline in both NL and SSc cells. Addition of dihydrolipoic acid (DHLA) significantly reduced hydroxyproline in both NL
and SSc cells. (C) Col I mRNA levels with or without PDGF stimulation at various time points. (D) The effect of transforming growth factor β (TGF-β)
on hydroxyproline levels was examined. TGF-β significantly increased hydroxyproline levels in both NL and SSc dermal fibroblasts, whereas DHLA
decreased it. (E) TGF-β induced Col I mRNA levels in both NL and SSc fibroblasts, and DHLA decreased them significantly. Results are expressed as
mean ± SEM. P < 0.05 was considered significant. BM, Basal medium; NL, Normal; NS, Nonstimulated.
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gest that DHLA not only affects PDGF-induced Col I
production but also acts on TGF-β-mediated fibrotic
processes.
Levels of matrix metalloproteinase, tissue inhibitor of
matrix metalloproteinase 1 and plasminogen activator
inhibitor 1
To further examine the effect of thiols on Col I degra-
dation, levels of MMP-1 in cell culture medium were de-
termined (Figure 4A). MMP-1 increased significantly
after PDGF stimulation in both NL and SSc fibroblasts.
In addition, PDGF-stimulated MMP-1 levels were sig-
nificantly lower in SSc dermal fibroblasts, which could
also contribute to the increased Col I expression seen inthese cells. Thiols did not alter MMP-1 significantly in
NL cells; however, they did increase MMP-1 in SSc cells
stimulated with PDGF. In particular, the presence of
DHLA resulted in a significant increase in PDGF-
stimulated MMP-1 levels in SSc.
Because MMP-3 converts pro-MMP-1 and pro-MMP-9
into their active forms, we also measured MMP-3 and
MMP-9 levels (Figure 4B). Similarly to MMP-1, PDGF
stimulated MMP-3 production in both NL and SSc cells.
In addition, MMP-3 was significantly lower in SSc fibro-
blasts under basal conditions. NAC did not appear to have
any effect on MMP-3, but DHLA increased MMP-3 sig-
nificantly in both NL and SSc cells. The lack of MMP-3 to
activate MMP-1 may exacerbate the accumulation of Col
I in SSc dermal fibroblasts.
Figure 4 MMP-1, MMP-3, TIMP-1 and PAI-1 expression; MMP-1/TIMP-1 ratio; and MMP-1 activity in fibroblasts. (A) Matrix metalloproteinase
1 (MMP-1) released into cell culture media after platelet-derived growth factor (PDGF), dihydrolipoic acid (DHLA) and/or N-acetylcysteine (NAC)
incubation. (B) MMP-3 released into cell culture media after PDGF, DHLA and/or NAC incubation. (C) Tissue inhibitor of matrix metalloproteinase
1 (TIMP-1) in cell culture media after PDGF, DHLA and/or NAC incubation. (D) The MMP-1/TIMP-1 ratio in normal (NL) and scleroderma (SSc)
dermal fibroblasts. (E) MMP-1 activity was significantly higher in NL dermal fibroblasts than in SSc cells. PDGF significantly increased MMP-1
activity in NL and SSc cells. Both DHLA and NAC appeared to increase MMP-1 activity significantly in SSc dermal fibroblasts when stimulated by
PDGF. (F) Plasminogen activator inhibitor 1 released from both NL and SSc dermal fibroblasts in the presence of PDGF, DHLA, and/or NAC. Results
are expressed as mean ± SEM. P < 0.05 was considered significant. BM, Basal medium; NL, Normal; NS, Nonstimulated.
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Unlike MMP-1 and MMP-3, the antioxidants did not
affect MMP-9, nor did PDGF show a consistent effect
on its production (data not shown). Similarly, the an-
tioxidants did not affect TIMP-1 levels (Figure 4C).
Although TIMP-1 was elevated in SSc dermalfibroblasts, the MMP-1/TIMP-1 ratio was significantly
lower in SSc fibroblasts, suggesting a shift that favors
a profibrotic phenotype in these cells (Figure 4D).
DHLA, but not NAC, increased the ratio significantly,
suggesting additional beneficial effects of DHLA on
these cells.
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activity, we measured endogenous MMP-1 activity in cell
culture media. MMP-1 activity was significantly higher in
NL cells compared to SSc dermal fibroblasts with or with-
out PDGF stimulation (Figure 4E). Neither NAC nor
DHLA had an effect on MMP-1 activity in NL cells. In
SSc dermal fibroblasts, Both DHLA and NAC increased
MMP-1 activity significantly.
The levels of PAI-1, an inhibitor for urokinase/tissue
type plasminogen activator which contributes to Col deg-
radation, were also examined (Figure 4F). PAI-1 released
from SSc fibroblasts was significantly higher, whereas the
thiols significantly reduced it. Considering this informa-
tion together, it is possible that DHLA decreases Col I
through decreasing PAI-1 and increasing MMPs.
Expression of α-smooth muscle actin
To examine whether DHLA affects the myofibroblast
phenotype in SSc, we examined αSMA expression. The
expression of αSMA was markedly elevated in SSc der-
mal fibroblasts, and DHLA reduced it (Figures 5A andFigure 5 The expression of α-smooth muscle actin in fibroblasts. (A) T
(n = 3 subjects). IgG, Immunoglobulin G. (B) Western blots (n = 4 subjects) s
(DHLA) on transforming growth factor β (TGF-β)–stimulated dermal fibroblB). In addition, we examined the effect of DHLA on
TGF-β-stimulated fibroblasts. As shown in Figure 5C,
TGF-β induced αSMA expression in both NL and SSc
fibroblasts, whereas adding DHLA to the culture de-
creased its expression.
Discussion
In this study, we show that the thiol antioxidant DHLA not
only decreased cellular peroxynitrites but also reduced p-
PDGFR, which is potentially due to its effect on the phos-
phatases that are involved in this pathway. Col I, αSMA
and PAI-1 decreased after DHLA treatment, whereas
MMP-1 and MMP-3 increased. In addition, DHLA in-
creased MMP-1 activity. It also decreased the ability of
TGF-β to induce Col I and αSMA expression in fibroblasts.
The beneficial effect of DHLA might also be due to replen-
ishing the antioxidative capacity in SSc dermal fibroblasts.
NAC is used as an antioxidant, and its effect in SSc has
been examined in various studies [1,18,21–23]. Consider-
ing the low oral bioavailability of NAC, which could par-
tially explain its limited therapeutic efficacy in clinicalhe immunofluorescent staining of α-smooth muscle actin (αSMA)
how results similar to those in (A). (C) Effect of dihydrolipoic acid
asts from healthy and scleroderma (SSc) subjects.
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much better absorption profile to treat SSc is an intriguing
strategy. LA and DHLA are soluble in both lipid and
aqueous environments. Because of this, LA has better bio-
availability than NAC; the bioavailabilities of 200 mg of
LA and NAC have been estimated to be 38% and 4%, re-
spectively [24,25]. Because DHLA has more reducing ac-
tivity than LA, it was chosen for our study. We were able
to use lower amounts of DHLA and achieve the same or a
better effect with it compared with NAC.
We attempted to measure plasma LA and DHLA levels
using liquid chromatography-mass spectrometry, but they
fell below the detection limit. Instead, we immunostained
fibroblasts and found that LA in SSc cells was lower. We
should note that the plasma levels of LA and DHLA in
healthy subjects have been reported to be approximately
30 ng/ml (that is, 150 nM) and 175 ng/ml (0.84 nM), re-
spectively [26,27], much lower compared to GSH (3.39 ±
1.04 μM) [28], which is the predominant form of cellular
thiol. In a separate study, the plasma GSH content in SSc
patients was significantly lower than in healthy controls:
170 ± 44 vs. 246 ± 46 μmol/g hemoglobin, respectively [6].
Although DHLA and LA are lower in abundance than
GSH, their reduction potential is more negative than that
of GSH and its oxidized form (−320 mV vs. −240 mV),
suggesting that DHLA can regenerate GSH and maintain
the ratio between GSH and it oxidized form GSSG in cells
[29,30]. Moreover, owing to their amphipathic nature and
smaller molecular sizes compared to GSH, the DHLA-LA
pair moves freely in both cytosol and lipid compartments
and is readily accessible to more proteins and enzymes
that are affected by redox signaling. Therefore, LA and
DHLA, whether endogenously or given externally, are in-
deed important in maintaining cellular function.
We also examined LIAS, a crucial enzyme involved in
the LA synthetic pathway. The significantly lower LIAS in
SSc fibroblasts might explain the lower LA levels in these
cells. However, plasma LIAS was significantly elevated in
patients with diffuse SSc. The reason for the discrepancy
is not clear. Nonetheless, we were able to determine the
source of the LIAS by measuring LIAS in culture media
from dermal fibroblasts, endothelial cells and monocytes.
It appears that only monocytes from healthy subjects and
SSc patients released detectable amounts of LIAS (Fig-
ure 1D). Similar to what we saw in the plasma, monocytes
from diffuse patients produced elevated amounts of LIAS
compared to healthy subjects, whereas those from limited
SSc patients did not. Interestingly, we could not detect
LIAS from monocytes isolated from patients with
rheumatoid arthritis (data not shown). The mechanism of
LIAS release in different disease settings appears to be a
complicated process and remains to be explored. It is
worth noting that 8-isoprostane, an oxidized lipid, was
also found to be elevated in plasma obtained from patientswith diffuse SSc or ILD (data not shown). It is possible
that LIAS is being produced and released from circulating
immune cells to counteract the increased oxidative stress
observed in SSc patients.
In recent years, the use of LA/DHLA has evolved from
antioxidants to antifibrotics. LA was observed to protect
against bleomycin-induced lung injury by suppressing
ROS and improving the MMP-1/TIMP-1 ratio [31]. Treat-
ment with LA also attenuated cardiac fibrosis in rats [32].
In a diabetic model, LA not only decreased oxidative dam-
age and Col I and αSMA expression in the heart but also
increased MMP-2 activity [33]. In addition, LA inhibited
the development of thioacetamide-induced liver fibrosis in
rats [34]. In a hepatic fibrosis mouse model, LA inhibited
the expression of Col I, αSMA and PAI-1 [35]. Our study
adds SSc skin fibrosis to the fibrotic diseases that have
been shown to be affected by LA/DHLA.
In SSc, fibroblasts differentiate into myofibroblasts, a
process characterized by excess production of αSMA. The
mechanism of DHLA’s lowering αSMA expression in our
study is not known. However, LA treatment has been
shown to decrease the expression of TGF-β [33] and affect
the redox-sensitive transcription factors activator protein 1
(AP-1) and specificity protein 1 (Sp1) [35]. In addition, it de-
creased connective tissue growth factor [32]. In hepatic stel-
late cells, DHLA inhibited TGF-β/PDGF activation through
the interruption of ROS-related phosphatidylinositol 3-
kinase/protein kinase B (PI3K/AKT) and mitogen-activated
protein kinase (MAPK) signaling [34]. Budisavljevic et al.
had similar results with kidney cells, where mesangial cell
transformation into myofibroblasts was completely pre-
vented by LA [36]. These authors showed that LA inhibited
the PDGF-activated extracellular signal-regulated kinase 1/2
(ERK1/2) pathway, suggesting that the increased expression
of αSMA in cultured mesangial cells could be modulated by
redox-sensitive signaling pathways.
Tissue fibrosis occurs when extracellular matrix (ECM)
turnover favors production of collagen and other ECM
proteins over degradation. Therefore, in this study, in
addition to the activation of Col I synthesis (that is,
p-PDGFR), we examined the key factors that degrade Col
I. MMPs are major proteolytic enzymes involved in de-
grading and remodeling the ECM. MMP-1 derived from
fibroblasts is known to degrade Col I and other collagens.
MMP-3 has a broad spectrum of proteolytic activity, in-
cluding degradation of collagen. Furthermore, MMP-3 is
required for maximal activation of pro-MMP-1 and pro-
MMP-9. In contrast, TIMP-1 and PAI-1 are natural in-
hibitors of MMPs and plasmin, thereby inhibiting ECM
degradation. In agreement with the results of other studies
[37–41], we found that MMP-1, MMP-3 and MMP-9 re-
lease by SSc dermal fibroblasts was significantly lower and
that TIMP-1 and PAI-1 were elevated. DHLA was able to
increase both MMP-1 and MMP-3 levels released from
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the MMP-1/TIMP-1 ratio increased significantly after
DHLA treatment, shifting these SSc cells from a profibro-
tic state to a relatively antifibrotic state. Moreover, DHLA
not only increased the expression of MMP-1 but also in-
creased MMP-1 activity after PDGF stimulation in SSc
dermal fibroblasts. This suggests that DHLA can alter
pathogenic processes that are important in SSc.
The expression of MMP is regulated by nuclear factor
κB (NFκB) [42] and oxidative stress [43,44]; therefore,
the presence of antioxidants can alter the expression of
MMPs. In our hands, the incubation of thiol antioxi-
dants increased the expression of MMP-1 and MMP-3
(Figure 4). However, MMP-9 expression was not altered
by the thiols. It appears that the expression of MMP-9 is
regulated by NFκB, AP-1 and the p38 MAPK pathway
[45–47] and that LA inhibits MMP-9 expression by in-
activating NFκB [48]. The involvement of these other
pathways (AP-1 and p38) tightly regulates the MMP-9
expression, and this could be the reason for the ineffec-
tiveness of the thiols used. On the other hand, TIMP-1
expression can be stimulated by a variety of agents, in-
cluding serum, growth factors, cytokines and viruses
[49,50]. Regulation of TIMP-1 expression involves the
activation of transcription factors, including AP-1, Sp1,
STAT (signal transducer and activator of transcription)
and Pea3/Ets families, as well as signaling pathways such
as the ERK1/2 pathway [51–53]. Similarly to MMP-9,
the complex regulation of TIMP-1 expression makes it
difficult to render its expression; hence, in our hands,
the use of thiol antioxidants did not affect TIMP-1 levels
in NL and SSc dermal fibroblasts.
What could be the possible mechanism by which the
thiols affect the expression of the phosphatases exa-
mined in this study? Transcription factors, such as NFκB
and AP-1, are regulated by the intracellular redox state.
They are implicated to be involved in the regulation of
expression of a variety of genes [54]. It has been shown
that LA and DHLA and NAC inhibit the NFκB pathway
[54–56]. NAC also inhibits AP-1 activation [57], whereas
the role of LA/DHLA on this pathway is unclear. It is
possible that the thiol antioxidants control the expression
of phosphatases through these redox-sensitive transcrip-
tion factors. Moreover, the expression of phosphatases can
be affected by oxidative stress [58]. The exact mechanism
by which the antioxidants increase SHP-2 and DEP-1
expression requires further investigation.
The PTP family is characterized by their signature
motif at their active site, HC(X)5R. This site contains an
essential cysteine residue that has a low pKa which is
susceptible to oxidation. Its ability to be oxidized re-
versibly acts as a redox regulatory mechanism for recep-
tor tyrosine kinases to control their phosphorylation
state. We and others have shown that when excessiveoxidative stress is present, the cysteine group is oxidized
and the activity is inactivated [1,59,60]. We also reported
that PTP1B was oxidized and subsequently inactivated
in SSc dermal fibroblasts [1]. This led to prolonged
p-PDGFR and increased Col I. Treatment with NAC re-
stored the activity and decreased p-PDGFR and Col I. In
this study, DHLA showed a similar effect. In addition to
PTP1B, we examined two other thiol-sensitive phospha-
tases that regulate p-PDGFR. Similar to PTP1B, these
phosphatases have a cysteine residue at their active site
that is required for their phosphatase activity. As shown
in Figure 2, DHLA increased activities of all three phos-
phatases in SSc fibroblasts. This is superior to NAC, be-
cause NAC had no effect on DEP-1 and SHP-2 activities.
It has been shown that thiol antioxidants are able to re-
generate enzyme − SH groups and restore the phos-
phatase activities [1,61,62]. Therefore, the mechanism by
which DHLA restores the enzyme activity is through re-
duction of the oxidized cysteine group at the active site.
Note that the catalytic activities of these phosphatases
are tightly regulated and that subcellular localization can
also affect substrate specificity. In other words, the
active site may have different susceptibility toward dif-
ferent thiol antioxidants. In addition, the antioxidant
capacity of the thiols used in this study is different (the
pKa at the thiol group differs), giving them different
catalytic activities toward the possible different oxidation
products (for example, −SOH, −SO2H, −SSR) at the
phosphatase active sites [61,63]. Moreover, because the
bioavailability of NAC is lower than that of LA/DHLA
and LA/DHLA has more desirable structural properties
that allow it to move freely in cellular compartments,
LA/DHLA could reach a higher concentration intra-
cellularly and hence be more accessible at the enzyme
active site compared to NAC. We speculate that these
are the reasons why NAC has no effect on SHP-2
activity (Figure 2C), but DHLA does. Nonetheless, the
increase in these phosphatase activities provides a poten-
tial mechanism for reducing p-PDGFR in SSc dermal
fibroblasts.
Conclusion
To our knowledge, this study is the first to show that
LA and LIAS are lower in SSc dermal fibroblasts. In
addition, DHLA was able to reverse the profibrotic
phenotype of these cells by decreasing p-PDGFR,
restoring the activities of phosphatases, lowering PAI-
1, and increasing both MMP-1 and MMP-3 expres-
sion as well as MMP-1 activity. Moreover, DHLA
lowered the expression of αSMA, suggesting that it
could reverse the myofibroblast differentiation of SSc
dermal fibroblasts. Hence thiol antioxidants, in par-
ticular LA or DHLA, could prove to be an effective
treatment in SSc.
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Additional file 1: Figure S1. Phosphatase expression in NL and SSc
dermal fibroblasts. SHP-2 mRNA in SSc dermal fibroblasts was significantly
lower than NL (P < 0.05, n = 6 subjects). On the other hand, DEP-1 mRNA
was significantly elevated in SSc dermal fibroblasts compared to NLs
(P < 0.05, n ≥ 5 subjects). The presence of NAC or DHLA did not alter
DEP-1 mRNA. NAC significantly increased SHP-2 mRNA in SSc cells,
whereas DHLA had no significant effect. Results are expressed as
mean ± SE, and P < 0.05 was considered significant.
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